- Home
- HES vs EW Comparison
HES vs EW Comparison
Compare HES & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HES
- EW
- Stock Information
- Founded
- HES 1920
- EW 1958
- Country
- HES United States
- EW United States
- Employees
- HES N/A
- EW N/A
- Industry
- HES Integrated oil Companies
- EW Industrial Specialties
- Sector
- HES Energy
- EW Health Care
- Exchange
- HES Nasdaq
- EW Nasdaq
- Market Cap
- HES 41.4B
- EW 40.7B
- IPO Year
- HES N/A
- EW 2000
- Fundamental
- Price
- HES $132.33
- EW $73.68
- Analyst Decision
- HES Buy
- EW Buy
- Analyst Count
- HES 9
- EW 20
- Target Price
- HES $164.18
- EW $79.45
- AVG Volume (30 Days)
- HES 1.6M
- EW 4.3M
- Earning Date
- HES 04-30-2025
- EW 04-23-2025
- Dividend Yield
- HES 1.51%
- EW N/A
- EPS Growth
- HES 11.25
- EW 201.77
- EPS
- HES 7.25
- EW 7.02
- Revenue
- HES $12,270,000,000.00
- EW $5,522,300,000.00
- Revenue This Year
- HES N/A
- EW $10.07
- Revenue Next Year
- HES $16.80
- EW $9.65
- P/E Ratio
- HES $18.22
- EW $10.54
- Revenue Growth
- HES 9.70
- EW N/A
- 52 Week Low
- HES $123.79
- EW $58.93
- 52 Week High
- HES $161.69
- EW $95.25
- Technical
- Relative Strength Index (RSI)
- HES 47.20
- EW 52.18
- Support Level
- HES $128.13
- EW $74.25
- Resistance Level
- HES $131.02
- EW $76.13
- Average True Range (ATR)
- HES 2.71
- EW 1.75
- MACD
- HES 0.80
- EW -0.02
- Stochastic Oscillator
- HES 71.05
- EW 56.51
About HES Hess Corporation
Hess is an independent oil and gas producer with key assets in the Bakken Shale, Guyana, the Gulf of Mexico, and Southeast Asia. At the end of 2023, the company reported net proved reserves of 1.4 billion barrels of oil equivalent. Net production averaged 391 thousand barrels of oil equivalent per day in 2023, at a ratio of 74% oil and natural gas liquids and 26% natural gas.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.